WHO vaccine-preventable diseases: monitoring system. 2019 global summary

Last updated 10-December-2019 (data as of 10-December-2019)
Next overall update June 2020
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 41'0701 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 45'8771 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2018  2017  2016  2015  2014  2000  1990  1980 
Total population 64'991  64'843  64'668  64'453  64'194  59'015  56'667  53'868 
Births 729  737  747  758  769  756  748  747 
Surviving infants 727  735  745  755  766  752  742  740 
Pop. less than 5 years 3'734  3'804  3'860  3'893  3'929  3'674  3'800  3'647 
Pop. less than 15 years 11'670  11'743  11'799  11'829  11'828  11'158  11'379  12'077 
Female 15-49 years 27'798  27'888  27'975  28'060  28'167  28'784  28'523  26'292 

Number of reported cases

(Click for retrospective incidence data for France)
Diphtheria
ChartChart
  14 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  2'921  519  79  157  267  10'000  1'244 
Mumps
ChartChart
  17'400 
Pertussis
ChartChart
  155  56  47  84  100 
Polio*
ChartChart
  10 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  26  33  208 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for France)
Vaccine year result method % card seen                                                
BCG          83  74 
DTP1          99  99  99  99 
DTP3          96  96  96  97  98  97  94 
IPV1         
HepB_BD         
HepB3          91  90  90  88  83  26 
Hib3          95  95  95  96  97  86 
JapEnc         
MCV1          90  90  90  91  91  84  71 
MCV2          83  80  80  79  77 
MenA         
PCV1          96  95 
PCV2          96  92  95 
PCV3          92  92  92  91  89 
Pol3          96  96  96  97  98  98  95 
Rota1         
RotaC         
RCV1          90  90  90  91  91 
TT2plus         
PAB         
VAD1         
YFV          80 
* indicates the country reported above 100% coverage.

  Next update: Mid July 2020

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for France)
BCG
ChartChart
  83  74  80 
DTP1
ChartChart
  99  99  99  99  99  99  97  92 
DTP3
ChartChart
  96  96  96  97  98  97  94  79 
HepB3
ChartChart
  90  90  90  88  83  26 
HepB_BD
ChartChart
 
Hib3
ChartChart
  95  95  95  96  97  86 
IPV1
  99  99  99  99 
MCV1
ChartChart
  90  90  90  91  91  84  71 
MCV2
ChartChart
  80  80  80  79  77 
PCV3
ChartChart
  92  92  92  91  89 
Pol3
ChartChart
  96  96  96  97  98  98  95  80 
RCV1
ChartChart
  90  90  90  91  91  84  71 
RotaC
 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 101  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2018 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; No B/M1/M2: children born in Guyanna and Mayotte (B), infant at risk (M1-M2)
DTaP 11-13, 25 years; Yes
DTaPHibHepBIPV 2, 4, 11 months; Yes
HepA_Adult 1st contact; +6-12 months; No professionnal at risk, adults at risk
HepB_Adult 1st contact; +1, +6 months; Yes Professionnal at risk (health professionnels, fireman, secourists)
HepB_Pediatric birth; Yes
HPV 11-13 years; +6 months; Yes Females 11-13 years: 2 doses (M0, +M6); females 14-19 years and MSM under 26 years: 3 doses (M0, +M2, +M6)
Influenza_Adult Yes elderly, pregnant women, healthcare workers, adults with chronic conditions, residents living in long-term care facilities
Influenza_Pediatric Yes children with chronic conditions
MenC_conj 5, 12 months; Yes
MMR 12, 18 months; Yes
Pneumo_conj 2, 4, 11 months; Yes
Pneumo_ps Yes adults at risk
TdaPIPV 6, 13, 25 years; Yes
TdIPV 45, 65 years; Yes
YF 9 months, 6 years; No French Guyana only; mandatory; one dose for children above 2 years and adults

Immunizaton indicators

Indicator Expected answer 2018  2017  2016  2015  2014  2013  2012 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  No  No  No  No 
What years does the MYP cover? number 2018-2022  2018-2022  2012-2017         
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 101  101  101  101  101  101  101 
Nº districts with DTP3 coverage >=80% number             89 
% of districts with DTP3 coverage >=80% From 0 to 100%             88 
Nº districts with measles (MCV1) coverage >=95% number            
% of districts with MCV1 coverage >=95% From 0 to 100%            

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  No  No 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.